Wells Fargo analyst Mohit Bansal maintained a Hold rating on Merck & Company yesterday and set a price target of $97.00. The company’s shares closed yesterday at $81.52. Elevate ...

New WHO guidelines endorse long-acting injectable lenacapavir for HIV prevention, Medicines Patent Pool expands licence for ...

A monthly pill would add to the growing number of choices for HIV preexposure prophylaxis, which is now seen as the best hope ...

Rahway, New Jersey Wednesday, July 16, 2025, 17:30 Hrs [IST] ...

NHS England agreed to reimburse Vertex's newest cystic fibrosis medicine. Meanwhile, Merck advanced a once-monthly PrEP pill ...

HIV pharma leaders are in Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced the initiation of the EXPrESSIVE Phase 3 ...

In a report released on July 10, Tycho Peterson from Jefferies maintained a Buy rating on Merck & Company, with a price target of $141.00. The company’s shares opened today at $83.43. Peterson covers ...

IAS 2025, the 13th IAS Conference on HIV Science, opened today with a call to accelerate access to long-acting HIV prevention and treatment innovations amid growing global funding challenges. Four ...